{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:47:27Z","timestamp":1788972447877,"version":"build-2803163510"},"reference-count":35,"publisher":"Georg Thieme Verlag KG","issue":"11","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Spinal muscular atrophy (SMA-5q) is a neurodegenerative disease characterized by progressive muscle atrophy, hypotonia, and weakness, with SMA 1 presenting symptoms within the first 6 months of life. Disease-modifying therapies have been approved, with better outcomes with earlier treatment.<\/jats:p><jats:p>\n          Objective\u2003To describe the safety and clinical efficacy of disease-modifying therapies based on SMN1 and SMN2 gene strategies concerning motor, respiratory, and bulbar function. Patients with SMA 1 were divided into 2 groups: those exclusively on nusinersen (group 1) and those transitioning to onasemnogene abeparvovec (OA) (group 2).<\/jats:p><jats:p>\n          Methods\u2003Over 18 months, patients were assessed using the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) scale, developmental milestones, ventilation needs and duration, nutritional support needs, consistency of food, and signs of dysphagia. There were ten patients, divided between the groups; in group 1, the average age for starting nusinersen was 53.6 (12\u2013115) months, and, in group 2, the age was 7 (1\u201312) months for nusinersen and 15.2 (10\u201319) months for OA.<\/jats:p><jats:p>\n          Results\u2003Our results indicate that 70% of patients reached some motor milestones, with group 1 increasing by 10.2 points on the CHOP-INTEND scale, while group 2 increased by 33 points. Additionally, 90% of the patients experienced no respiratory decline, and 30% maintained oral feeding. No serious adverse effects or deaths were recorded.<\/jats:p><jats:p>\n          Conclusion\u2003Both groups showed improvement in motor function and stabilization of respiratory and bulbar function, with the difference between the groups possibly being related to the earlier treatment initiation. Thus, the present study provides valuable insights into the real-world safety and clinical efficacy of disease-modifying therapies for SMA 1 patients.<\/jats:p>","DOI":"10.1055\/s-0044-1791757","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:13:17Z","timestamp":1730938397000},"page":"001-008","source":"Crossref","is-referenced-by-count":4,"title":["Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies"],"prefix":"10.1055","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9429-1875","authenticated-orcid":false,"given":"Brenda Klemm Arci Mattos de Freitas","family":"Alves","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, P\u00f3s-gradua\u00e7\u00e3o em Sa\u00fade Materno-infantil, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-4354","authenticated-orcid":false,"given":"Alexandra Prufer de Queiroz Campos","family":"Araujo","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Faculdade de Medicina, Departamento de Pediatria, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8006-9435","authenticated-orcid":false,"given":"Fl\u00e1via Nardes dos","family":"Santos","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Faculdade de Medicina, Departamento de Pediatria, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-0189","authenticated-orcid":false,"given":"M\u00e1rcia Gon\u00e7alves","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Faculdade de Medicina, Departamento de Pediatria, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","article-title":"Spinal muscular atrophies","volume":"62","author":"B T Darras","year":"2015","journal-title":"Pediatr Clin North Am"},{"issue":"08","key":"ref2","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: a timely review","volume":"68","author":"S J Kolb","year":"2011","journal-title":"Arch Neurol"},{"issue":"04","key":"ref3","doi-asserted-by":"publisher","first-page":"e33572","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"T O Crawford","year":"2012","journal-title":"PLoS One"},{"issue":"03","key":"ref4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","article-title":"A positive modifier of spinal muscular atrophy in the SMN2 gene","volume":"85","author":"T W Prior","year":"2009","journal-title":"Am J Hum Genet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next","volume":"21","author":"B Wirth","year":"2020","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"04","key":"ref6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/hmg\/4.4.631","article-title":"Deletions in the survival motor neuron gene on 5q13 in autosomal recessive spinal muscular atrophy","volume":"4","author":"N R Rodrigues","year":"1995","journal-title":"Hum Mol Genet"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/(SICI)1096-8628(19971003)72:1<51::AID-AJMG11>3.0.CO;2-T","article-title":"SMN(T) and NAIP mutations in Canadian families with spinal muscular atrophy (SMA): genotype\/phenotype correlations with disease severity","volume":"72","author":"L R Simard","year":"1997","journal-title":"Am J Med Genet"},{"issue":"02","key":"ref8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/hmg\/5.2.257","article-title":"Molecular analysis of the SMN and NAIP genes in Spanish spinal muscular atrophy (SMA) families and correlation between number of copies of cBCD541 and SMA phenotype","volume":"5","author":"E Velasco","year":"1996","journal-title":"Hum Mol Genet"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","article-title":"An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)","volume":"15","author":"B Wirth","year":"2000","journal-title":"Hum Mutat"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1086\/301608","article-title":"De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling","volume":"61","author":"B Wirth","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"03","key":"ref11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"M Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"09","key":"ref12","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3390\/ijms21093297","article-title":"New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?","volume":"21","author":"T H Chen","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"14","key":"ref15","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/WNL.0000000000006281","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study","volume":"91","author":"K Aragon-Gawinska","year":"2018","journal-title":"Neurology"},{"issue":"18","key":"ref16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"R S Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of Age and Motor Function in a Phase 1\/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy","volume":"98","author":"L P Lowes","year":"2019","journal-title":"Pediatr Neurol"},{"issue":"18","key":"ref18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"J R Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"07","key":"ref19","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy","volume":"78","author":"J R Mendell","year":"2021","journal-title":"JAMA Neurol"},{"issue":"03","key":"ref20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ana.25533","article-title":"Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data","volume":"86","author":"M Pane","year":"2019","journal-title":"Ann Neurol"},{"issue":"03","key":"ref21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"R S Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"02","key":"ref22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"E Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"01","key":"ref23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0044-1779503","article-title":"Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy","volume":"82","author":"E Zanoteli","year":"2024","journal-title":"Arq Neuropsiquiatr"},{"issue":"09","key":"ref24","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1055\/s-0043-1772832","article-title":"Brazilian version of the CHOP INTEND scale: cross-cultural adaptation and validation","volume":"81","author":"R MR Alves","year":"2023","journal-title":"Arq Neuropsiquiatr"},{"issue":"01","key":"ref25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13023-022-02455-x","article-title":"Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study","volume":"17","author":"C Cances","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"09","key":"ref26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"R S Finkel","year":"2014","journal-title":"Neurology"},{"issue":"06","key":"ref27","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"S J Kolb","year":"2017","journal-title":"Ann Neurol"},{"issue":"01","key":"ref28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13023-020-01356-1","article-title":"Longitudinal natural history of type I spinal muscular atrophy: a critical review","volume":"15","author":"E Mercuri","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"05","key":"ref29","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study","volume":"63","author":"G Acsadi","year":"2021","journal-title":"Muscle Nerve"},{"issue":"08","key":"ref30","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1007\/s12035-017-0831-9","article-title":"Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular Atrophy","volume":"55","author":"A Govoni","year":"2018","journal-title":"Mol Neurobiol"},{"issue":"08","key":"ref31","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.3390\/jcm12082839","article-title":"Effectiveness of Nusinersen in Type 1, 2 and 3 Spinal Muscular Atrophy: Croatian Real-World Data","volume":"12","author":"A Belan\u010di\u0107","year":"2023","journal-title":"J Clin Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data","volume":"39","author":"J Erdos","year":"2022","journal-title":"Eur J Paediatr Neurol"},{"issue":"02","key":"ref33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/brain\/awac252","article-title":"Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy","volume":"146","author":"A Pechmann","year":"2023","journal-title":"Brain"},{"issue":"03","key":"ref34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort","volume":"6","author":"S A Al-Zaidy","year":"2019","journal-title":"J Neuromuscul Dis"},{"issue":"01","key":"ref35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12883-023-03133-6","article-title":"Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study","volume":"23","author":"G M Stettner","year":"2023","journal-title":"BMC Neurol"},{"issue":"02","key":"ref37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/JND-200533","article-title":"Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen","volume":"8","author":"R de Holanda Mendon\u00e7a","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"02","key":"ref38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany","volume":"5","author":"A Pechmann","year":"2018","journal-title":"J Neuromuscul Dis"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1791757.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:13:22Z","timestamp":1730938402000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1791757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,8,26]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["s00441791757"],"URL":"https:\/\/doi.org\/10.1055\/s-0044-1791757","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}